In recent years, inhibitors of poly(ADP-ribose) polymerase 1 (PARP1) have revolutionised the therapy of ovarian cancer, particularly in tumours that have preexisting damage to their homologous recombination [1]. This evidence concerns the gene PARP1 and neoplasm.